Iterum Therapeutics (ITRM) Invested Capital (2017 - 2022)
Historic Invested Capital for Iterum Therapeutics (ITRM) over the last 6 years, with Q3 2022 value amounting to $33.2 million.
- Iterum Therapeutics' Invested Capital fell 4205.61% to $33.2 million in Q3 2022 from the same period last year, while for Sep 2022 it was $33.2 million, marking a year-over-year decrease of 4205.61%. This contributed to the annual value of $55.6 million for FY2021, which is 26899.07% up from last year.
- Per Iterum Therapeutics' latest filing, its Invested Capital stood at $33.2 million for Q3 2022, which was down 4205.61% from $45.5 million recorded in Q2 2022.
- Iterum Therapeutics' 5-year Invested Capital high stood at $133.0 million for Q2 2018, and its period low was -$40.3 million during Q3 2020.
- Its 5-year average for Invested Capital is $31.8 million, with a median of $41.0 million in 2021.
- In the last 5 years, Iterum Therapeutics' Invested Capital tumbled by 222235.67% in 2020 and then skyrocketed by 26899.07% in 2021.
- Over the past 5 years, Iterum Therapeutics' Invested Capital (Quarter) stood at $72.6 million in 2018, then crashed by 128.14% to -$20.4 million in 2019, then plummeted by 60.99% to -$32.9 million in 2020, then skyrocketed by 268.99% to $55.6 million in 2021, then plummeted by 40.36% to $33.2 million in 2022.
- Its last three reported values are $33.2 million in Q3 2022, $45.5 million for Q2 2022, and $53.1 million during Q1 2022.